CN114480387B - 一种金黄色葡萄球菌组成型启动子、表达载体及其构建方法、重组菌株及应用 - Google Patents
一种金黄色葡萄球菌组成型启动子、表达载体及其构建方法、重组菌株及应用 Download PDFInfo
- Publication number
- CN114480387B CN114480387B CN202210006664.3A CN202210006664A CN114480387B CN 114480387 B CN114480387 B CN 114480387B CN 202210006664 A CN202210006664 A CN 202210006664A CN 114480387 B CN114480387 B CN 114480387B
- Authority
- CN
- China
- Prior art keywords
- staphylococcus aureus
- constitutive promoter
- expression vector
- expression
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000191967 Staphylococcus aureus Species 0.000 title claims abstract description 47
- 239000013604 expression vector Substances 0.000 title claims abstract description 37
- 238000010276 construction Methods 0.000 title abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 56
- 230000014509 gene expression Effects 0.000 claims abstract description 37
- 239000013612 plasmid Substances 0.000 claims description 23
- 229960005091 chloramphenicol Drugs 0.000 claims description 9
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 239000013598 vector Substances 0.000 claims description 6
- 239000013605 shuttle vector Substances 0.000 claims description 4
- 241000588722 Escherichia Species 0.000 claims description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 3
- 239000005090 green fluorescent protein Substances 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 108091008146 restriction endonucleases Proteins 0.000 claims description 3
- 206010041925 Staphylococcal infections Diseases 0.000 claims 2
- 101150066002 GFP gene Proteins 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 claims 1
- 208000015339 staphylococcus aureus infection Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 206010059866 Drug resistance Diseases 0.000 abstract description 5
- 230000001018 virulence Effects 0.000 abstract description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 3
- 238000009412 basement excavation Methods 0.000 abstract description 3
- 230000008844 regulatory mechanism Effects 0.000 abstract description 3
- 230000002924 anti-infective effect Effects 0.000 abstract description 2
- 229940124350 antibacterial drug Drugs 0.000 abstract description 2
- 230000000813 microbial effect Effects 0.000 abstract description 2
- 238000012827 research and development Methods 0.000 abstract description 2
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 23
- 101150106935 purR gene Proteins 0.000 description 11
- 108010053835 Catalase Proteins 0.000 description 10
- 238000010367 cloning Methods 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 102000016938 Catalase Human genes 0.000 description 6
- 102100026189 Beta-galactosidase Human genes 0.000 description 5
- 108010005774 beta-Galactosidase Proteins 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000006978 adaptation Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000003208 gene overexpression Methods 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 241001573946 Psara Species 0.000 description 2
- 241000284708 Sarcophaga alpha Species 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 101150094188 sarA gene Proteins 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 101150040471 19 gene Proteins 0.000 description 1
- 101150090724 3 gene Proteins 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100025169 Max-binding protein MNT Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 101000693691 Salmonella typhimurium (strain 14028s / SGSC 2262) Salmonella anti-inflammatory response activator Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- SWXQKHHHCFXQJF-UHFFFAOYSA-N azane;hydrogen peroxide Chemical compound [NH4+].[O-]O SWXQKHHHCFXQJF-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000006825 purine synthesis Effects 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/34—Vector systems having a special element relevant for transcription being a transcription initiation element
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明提供了一种金黄色葡萄球菌组成型启动子、表达载体及其构建方法、重组菌株及应用,涉及微生物分子生物学技术领域。所述组成型启动子包含如SEQ ID NO.1至SEQ ID NO.19所示的任一核苷酸序列。本发明能够提供19个金黄色葡萄球菌组成型启动子,且具有不同的表达活性,能够供基因不同水平的持续性表达。另一方面,本发明还提供了一种包含上述组成型启动子的表达载体,以实现目的基因在金葡菌中不同强度地持续性表达,进而为实现金葡菌耐药及毒力相关基因功能及调控机制的深度挖掘提供工具,并为新型抗菌药物的研发及临床抗感染治疗方案的制定提供新思路。
Description
技术领域
本发明涉及微生物分子生物学技术领域,尤其是涉及一种金黄色葡萄球菌组成型启动子、表达载体及其构建方法、重组菌株及应用。
背景技术
金黄色葡萄球菌是目前造成临床感染最常见的病原菌之一。随着耐甲氧西林金黄色葡萄球菌(Methicillin-resistant S.aureus,MRSA)的出现和流行,世卫组织已将MRSA列入“重要等级”病原菌行列。MRSA之所以对人类的健康和生病造成严重威胁,主要是因为其严重的耐药性及复杂多变的免疫逃逸机制,使其在体内很难被彻底清楚,非常容易造成复发。因此,对金葡菌耐药及毒力相关基因功能及调控机制的深度挖掘,将为新型抗菌药物的研发及临床抗感染治疗方案的制订提供新的思路。
对金葡菌毒力基因及功能未知基因的研究采用的常规方法包括基因敲除、回补及过表达等。目前,金葡菌基因敲除、回补的基因工具及方法已被成功建立和广泛应用。但是,金葡菌基因过表达的基因工具却非常缺乏,这主要是因为缺乏可用的启动子。用于基因表达的启动子可分为两大类:诱导性启动子和组成型启动子。金葡菌中应用的诱导性启动子主要包括木糖诱导性启动子、异丙基-β-d-硫代半乳糖苷(IPTG)诱导性启动子及四环素诱导性启动子等。虽然这些启动子都能在金葡菌中有效的过表达基因,但是在应用的过程中具备一定的局限性,比如木糖型诱导启动子的活性通常会受葡萄糖的抑制,而葡萄糖是真核细胞中常见的物质,因此木糖型诱导启动子在金葡菌的动物及细胞感染模型中的应用受到限制。此外,所有诱导性启动子都需要诱导剂的诱导,而诱导剂的加入通常会影响金葡菌的正常生理代谢,甚至造成一些无法预期的表型出现。而组成型启动子不需要诱导剂的诱导便能让目标基因成功表达,是实现基因过表达的理想途径。
然而目前在金葡菌中用于基因持续性表达的组成型启动子非常少,主要有金葡菌转录调控因子SarA基因的启动子PsarA及编码荚膜基因启动子Pcap。组成型启动子的活性是固定的,因此用于基因表达时,基因的表达水平是固定的,如果想要不同水平地持续型表达基因,则需要不同强度的组成型启动子,以供基因不同水平的持续性表达。
发明内容
本发明的第一目的在于提供一种金黄色葡萄球菌组成型启动子,本申请提供的金黄色葡萄球菌组成型启动子具有不同的表达活性,可以供基因不同水平的持续性表达。
本发明的第二目的在于提供一种包含金黄色葡萄球菌组成型启动子的表达载体,以实现目的基因在金葡菌中不同强度地持续性表达,进而为实现金葡菌耐药及毒力相关基因功能及调控机制的深度挖掘提供工具。
为实现上述目的,本发明提供了以下技术方案:
本发明提供的一种金黄色葡萄球菌组成型启动子,所述组成型启动子包含如SEQID NO.1至SEQ ID NO.19所示的任一核苷酸序列。
根据一种优选实施方式,具有如SEQ ID NO.1至SEQ ID NO.19所示的核苷酸序列的所有组成型启动子具有不同的表达活性,且在金黄色葡萄球菌接种后的适应期、对数期和稳定期均能够高水平表达。
本发明还提供了一种包含上述金黄色葡萄球菌组成型启动子的表达载体。
根据一种优选实施方式,所述表达载体是在大肠杆菌-金黄色葡萄球菌穿梭载体质粒插入上述组成型启动子构建而成。
本发明还提供了一种所述的表达载体的构建方法,包括:
在大肠杆菌-金黄色葡萄球菌穿梭载体质粒pBUS1-Pcap-HC的Bgl II位点插入氯霉素抗性基因,得到携带氯霉素抗性基因的pBUS1_Pcap_HC_cat质粒;
利用限制性内切酶Kpn I和Nde I去除pBUS1_Pcap_HC_cat质粒中的Pcap启动子,并替换为权利要求1所述的组成型启动子,得到携带不同组成型启动子的基因表达载体。
基于上述技术方案,本发明的一种金黄色葡萄球菌组成型启动子、表达载体及其构建方法、重组菌株及应用至少具有如下技术效果:
本发明提供的金黄色葡萄球菌组成型启动子包含如SEQ ID NO.1至SEQ ID NO.19所示的任一核苷酸序列。因此本发明能够提供19个金黄色葡萄球菌组成型启动子,且具有不同的表达活性,能够供基因不同水平的持续性表达。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1是本发明实施例1中鉴定金葡菌在3个生长时期高表达基因的示意图。
图2是本发明实施例1中将扩增出来的启动子序列克隆至包含β-半乳糖苷酶的报告基因质粒中的过程图;
图3是本发明实施例1中30个启动子的活性显色情况;
图4是本发明实施例2中基于活性启动子序列表达载体的构建过程;
图5是本发明实施例2中基因表达载体的基因转录水平及目的基因表达情况;
图6是本发明实施例2中所构建的表达载体表达内源性基因过氧化氢酶基因及转录抑制子purR基因的示意图。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚,下面将对本发明的技术方案进行详细的描述。显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动的前提下所得到的所有其它实施方式,都属于本发明所保护的范围。
实施例1
本实施例1提供了金黄色葡萄球菌组成型启动子的筛选过程,具体如下:
1.1、鉴定金黄色葡萄球菌在适应期、对数期及稳定期同时高表达的基因。
将金葡菌接种于TSB肉汤培养基,每小时测定OD600吸光值,绘制出金葡菌生长曲线,如图1A所示。在金葡菌接种后的适应期LP(2h)、对数期EP(6h)及稳定期SP(10h)收集细菌样本,送至南京派森诺基因公司进行转录组测序及数据分析。利用转录中的FPKM(FragmentsPer Kilobase per Million)值,将FPKM≥1500的基因判定为高表达基因,如图1B所示,对LP,EP,SP时期的高表达基因进行交叉分析,筛选出30条同时在3个生长时期高表达的基因,如图1C所示。
1.2、高表达基因启动子序列的扩增及克隆。
以S.αureusUSA300_FPR3757基因组DNA为模板,利用高保真PCR酶GXL Premix(Takara),PCR扩增出30条高表达基因的30个启动子序列(P1-P30)及阳性对照sarA基因启动子(P31),引物见下表1。扩增出的启动子PCR产物经纯化后,利用无缝克隆试剂盒ClonExpress II One Step Cloning Kit(Vazyme),将扩增、纯化的启动子片段,克隆至EcoR I和Pst I线性化的β-半乳糖苷酶报告基因质粒中,如图2所示。启动子序列以其对应的Gene locus为命名,如基因SAUSA300_RS10930对应的启动子命名为P10930。高表达基因信息及启动子序列大小见下表2。将扩增出来的启动子序列,克隆至包含β-半乳糖苷酶的报告基因质粒中,如图2所示。
表1扩增高表达基因引物序列
表2高表达基因信息及启动子信息
1.3、高表达基因启动子序列的活性鉴定。
将构建好的所有质粒分别转化至S.αureusUSA300_FPR3757菌株中。挑取目的菌单菌落接种于10mL TSB培养基中。次日,取100μL接种于10mL TSB培养基中培养2h,取5μL菌液滴至含有25μg/mL氯霉素和200μg/mL X-Gal(5-bromo-4-chloro-3-indolyl-β-D-galactoside)的TSA固体培养基上。随后于30℃培养2天,观察菌落颜色。若启动子有活性,将驱动lacZ基因表达,产生β-半乳糖苷酶。产生的β-半乳糖苷酶将与X-Gal反应生成蓝色物质。结果如图3所示,克隆的30个启动子中有19个启动子有活性,显示出蓝色菌落。其中P31代表sarA基因启动子,作为阳性对照,NG代表无启动子,作为阴性对照。因此,具备活性的19个启动子序列被鉴定出,19个组成型启动子的核苷酸序列具体如下:
P1 P10930,
SEQ ID NO.1:
TTTTACACCACTCTCCTCACTGTCATTATACGATTTAGTACAATCTTTTATCATTATATTGCCTAACTGTAGGAAATAAATACTTAACTGTTAAATGTAATTTGTATTTAATATTTTAACATAAAAAAAATTACAGTTAAGAATAAAAAACGACTAGTTAAGAAAAATTGGAAAATAAATGCTTTTAGCATGTTTTAATATAACTAGATCACAGAGATGTGATGGAAAATAGTTG。
P2 P13425,
SEQ ID NO.2:
GGAGATTGGGTTAAAAAGGCGAAGAATGAACTGGATGATATTAGTAAGAAATTAAAAAATATTCAAAGAACGGAAGTTTAATAGCTTATATGATTCTTGGAGCTAAGACAGCATGCGTTCATTCATGCCATTATTAATATAAGCACCGCAACAAAAAAGCTTCTAATGTGATACAGGAACCTCATATTCCGTATCATGTTAGAAGCTTTTAATGTCTAAAGAACATCTACATTTTATCATATTTTCTGACTTATTAAACTTTTATATAATTAAATATTTCTTAATTTTCCAAAATAGTGATAAATTTGTGAAATACATCACAAATCCCTTTATTTATTTGGAAATTCATGTAATATTAGACTTGTAAGAAGTTAATAAATAGAGAGAGACGAGAGAGTTTATATAAATACTATATAAACATTGGAGTGATGATT。
P3 P01490,
SEQ ID NO.3:
AATAACCATTTAATCCTTTATGTATTTAATTTAATTTTAGTATACACATTTATATTACAAAAATGAATGGTTAATTAAAAATATATGGGTATATTCAATATATTTATTTAAAAAAAGCTAAAAATACTTAAAAAACTATATACATATACTAATAATTTATATATTATTTGAGTAAGGAGCACTTTTTCAAAAAATAGTGTCCCTAAAAAGTTTTGATAAACTTAAAATATTCAGGAGGTTTCTAGTT。
P4 P05790,
SEQ ID NO.4:
ACGTTTAACAACACAAGAATTATTATATCTAAATGAACTTAAATTAGCAATACCTTGTAAATAAAAAATGTTTATATTTTTCACTATTATAGAGCTATTTATCTAAAAAGGTTCAATAAGACTTAAATACGAATTCAGGCAACTTAATTGTGTTAAATACAGTTTTGAATGCCTAACTGTATTTCTTTTCTCTTTAAAATACAGTTAAGTACATTATAAGATGTTGTGCGGATAAACAAACTAATTGTATCAAATTTATTTTAAAATAACAACAACAAAACGATAAGCGAATAACATTTCGGTGATTTAAAAGCTACGCACGTTTTTGTTATCTTCAAATTTAAATTTTAAGGAGTGTTTTCA。
P5 P12390,
SEQ ID NO.5:
TTAATATAAAAAATATCAAATCAAACACGTTGATATAGATTAAAATTTTAAAAGTTTACATATCAGTTAAGATACAAAATATTCAGACTAATAATTTTCAATTTGGCAAAATATCTTAAACATCAAATTATTATAAGAAATAAATGTATTTAACCATATTCTAGTAATAAAAATATTGAATTTTTATACTTATTTGTTTAGAATGAACTTTATAACATAGTTGGATAGAGTTTCGATTTAATAAATTACATGTGAACCTTGCTACAACAAGATGTGCATCAGAGGAGTGGTTTAATA。
P7 P04400,
SEQ ID NO.6:
ATATTAATGGCTCAGTAACGTGATGTTGCTGGGCTTTTTAATTTAAACAGGTATTTATATGATATTTAGGAATGAGATGCTATTACGGATAAAGTAAAATCCTATATGCATGCGTGCTACTCATTTATTCTTATTTTTAATTTCACATGGCTAGTGACTAATACATCATAAATCATTAGTGATTCTTTATTATTTCAGTCCCACTCCCTCAAGTTAATGATGAATCTATTTCGCTAGTTATAAAATGACGTCAAATCAATATCAAAAATTATTTAAGTAAAATGTTTAGATAATTTTTCAGTGGGTAAGTATTATATATAACATTTAATTATTCCGAGGAGGCATTTATT。
P8 P10935,
SEQ ID NO.7:
CAACTATTTTCCATCACATCTCTGTGATCTAGTTATATTAAAACATGCTAAAAGCATTTATTTTCCAATTTTTCTTAACTAGTCGTTTTTTATTCTTAACTGTAATTTTTTTTATGTTAAAATATTAAATACAAATTACATTTAACAGTTAAGTATTTATTTCCTACAGTTAGGCAATATAATGATAAAAGATTGTACTAAATCGTATAATGACAGTGAGGAGAGTGGTGTAAAA。
P10 P00165,
SEQ ID NO.8:
ACATATCGTGAGCAATGAACTGATTATACTTAACATTAAAAAAGATGATAACACCTTCTACACCTCCATATCACAAAAATTATAACATTATTTTGACATAAATACTACATTTGTAATATACTACAAATGTAGTCTTATATAAGGAGTATA。
P11 P02850,
SEQ ID NO.9:
TATAACTTGTTTTGACTAGCTAGCCTAGGTTAAAATACAAGGTGAGCTTAAATGTAAGCTATCATCTTTATAGTTTGATTTTTTGGGGTGAATGCATTATAAAAGAATTGTAAAATTCTTTTTGCATCGCTATAAATAATTTCTCATGATGGTGAGAAACTATCATGAGAGATAAATTTAAATATTATTTTTAATTAGAATAGGAGAGATTTTATA。
P12 P03960,
SEQ ID NO.10:
GGGTGTAAATTATATGCTAAAAATATCAGAAAATTCAAAGTGTTTGCGTTTGCACGATAGCGTAAAAATGTTAAAATATAATAAAGAGTTACCAATAAAGAGGTTTAAGGAGAGATTACT。
P13 P05175,
SEQ ID NO.11:
CTAGCCATCATTTTCAATTTATTAGACAATTTCAAACTTTTTTTATTTTCATTCAATTAACCTTTAATTGAAAGCTATTCTCAACTTTCCTTTTAAATATGAAGCAATTTTTTCAAAAACGCTATTAGTCACAAAATGTACACATAATTTTAACAAATGTGTGAACCCACGTCACACCTTGATTTATCAACATTTTTGATACAATTTTATTAATTTTTTTCCCATAAGCCCTTGTAAATATTGTGTAATAACTTAAAATTAATGTTAAGCCCTACATTTGTAGTATTAGGAGGTCAAAAAA。
P14 P11445,
SEQ ID NO.12:
CTTTATCCTCCAATCTACTTATAAAATATTGTAATTAATGACTACATATTATGCAACGGCTTAAATTGTATAAAAATGTATACGTTTGCATTTAGTATAACTATCGCATTTTTCAAAAAATACACATTTAATCTGCAGTATTTCAATGCATTGACGCTATTTTTTTGATATAATTACTTTGAAAAATACGTGCGTAAGCACTCAAGGAGGAACTTTC。
P15 P12155,
SEQ ID NO.13:
ATTCATTCACCACCGTTCTTATGACTAATTATATAGAATAATTTTCAATGATAATAATAAAATGATTCAAGGTACGAATTTACAATAAAGAAGGAAATAAAAAATATCTCGAAAATAGTTGAACTGACTAAGTATATAAAGTAAAATATAAAAGTATGTGTTAGACAGATAGAAAAATTATGTGAAAAGCCTTGATTTATCGATGTTTTTCGTGTAATATAACTAACGTTGGACTTTAAGAAAAGCGATGAAGCGAAAGGTTACTGACACACCCGGCCGCTTTGCCATGGCGCTGTGTAAGATAGTTTTCGTGGAGAAGTCTATCACTAAATGTAGACGAATAAGGAGGGAAAATT。
P17 P11990,
SEQ ID NO.14:
TTGCCATTGACAAAAAGCTTGTGAAATTATAAGATTATTAACGGTATTGTTTTATATCCACCCCACGATAAGCCCCGGAAACTTATTGTGTTACAAGATATATAAGCAGAAACGAACAACAGTTAACAAAATAAATGAAATTAAACGTTTTAAAAATGAAACAAATGAAATCATCTATTAGGTTATGAAACTGTTTATAGCTTGAATAGAAGCATTTATTTTTTAGGAGGACAATTATT。
P19 P11815,
SEQ ID NO.15:
TTAATAATGAGGTTTTATTTACAAAAACTAGGGAATATATTACTAAATGGTACTTCATCTTATATATTAAAAATAAATTTAAAGTTATTAATTTATTATGTTTAAGAAAAAAACTGATGGGTACATATTTAATATGTTTTTAAATTAACTTTAACTAAGGAGGTGTCGTTAGGG。
P20 P08825,
SEQ ID NO.16:
TTTTTGTACGTCAAAACTTATACAAAAATTTTAAAAATAATGTAAGCACGAAACTTTTAATTAGTACACAATTGATAACATTTTTCAACGTTCATCATTTTGTCAAAAACTCAAAAGTAAATTAGAAAGATTATAATTTATTTAAGCATCGTACTTAATTGGATTTTAAATTATGTTATAATATTTGTATTGTTAGTATATATGGGGGCGTTTCAA。
P21 P02795,
SEQ ID NO.17:
TTAACAATTAAAGTTATTAAACTAACCAAAAGATAAAAAAGAGTATTGATTTTTTAATTAGAAAAGTGTTAAAATTATGTGGTCGCGCTTTTAGAGCGCCCATTTCGTCACGAAATGTTAAGAGTGGGAGGGCAAAACTGAGCCCTGTGACCACATCACGATATCAAGGAGGTGCACATC。
P24 P02805,
SEQ ID NO.18:
TAAATGATATAAACAATTACAGGCTGAAAGAAATATCTTTCAGTCTGTAAAAATATATTGACAATAAGTAATTTCCAAGTTATATTACTTATTGTGATTATTTTACCTAAGACAGTAGGAGTTATTTATAACTTAAAATTTATCCTGCCGAGGCTAAAATTGACTTGAACGTGATGATCTATGATCTTTCAAGCACTTTTTGCCGTGGGTAGAAAGTGCTTTTTTTATTAATTTTAAAAAAAGCACCAAAAATTTAAATGGAGGTGTCTGA。
P25 P08620,
SEQ ID NO.19:
GAATATGTAGATACAAGTGAAGATTTAGACGGATACATGTTTTATATTTAATCGTATAAATACTATACTATAACATAAAAACTTCATATTATAATGTTTAGCGAACCTCCTTAGTGGTATATAAATATATACATCCAAGGAGGTTTCACT。
P31 PsarA:
SEQ ID NO.20:
CTGATATTTTTGACTAAACCAAATGCTAACCCAGAAATACAATCACTGTGTCTAATGAATAATTTGTTTTATAAACACTTTTTTGTTTACTTCTCATTTTTAATTAGTTATAATTAACTAAATAATAGAGCATTAAATATATTTAATAAAACTTATTTAATGCAAAATTATGACTAACATATCTATAATAAATAAAGATTAGATATCAATATATTATCGGGCAAATGTATCGAGCAAGATGCATCAAATAGGGAGGTTTTAAAC。
实施例2
本实施例提供了包含实施例1所述的活性组成型启动子的表达载体的构建,具体如下:
2.1、基于活性启动子序列表达载体的构建及评价。
本发明中基因表达载体的构建是基于大肠杆菌-金黄色葡萄球菌穿梭载体质粒pBUS1-Pcap-HC得来,如图4A所示。由于原始质粒只携带四环素抗性基因,而许多金葡菌对四环素具有天然抗性,因此我们首先在原始质粒的Bgl II位点插入了氯霉素抗性基因:以质粒pBT2(Addgene购买)为DNA模板,引物F(5’-ATCTTTTACTCAGCAATCGCCGTTAGAAAACCGACTGTAAAAAGT-3’)及R(5’-GAGAGAGTTCAAAATTGATCCTCGGCAATAGTTACCCTTATTATCAAG-3’),利用高保真PCR酶GXL Premix(Takara)扩增出完整氯霉素抗性基因片段。PCR产物经纯化后,利用无缝克隆试剂盒ClonExpress II One Step Cloning Kit(Vazyme),将氯霉素抗性基因片段克隆至Bgl II线性化的pBUS1-Pcap-HC质粒中,得到质粒pBUS1_Pcap_HC_cat,如图4B所示。随后利用限制性内切酶Kpn I和Nde I将pBUS1_Pcap_HC_cat质粒中的Pcap启动子序列切掉,采用同样的克隆方法,将Pcap启动子序列替换成本发明鉴定的有活性的19个启动子序列,如图4C所示。生成19个携带不同组成型启动子活性的基因表达载体,见下表3。
表3携带不同组成型启动子活性的基因表达载体
2.2、基因表达载体评估。
为了评估所构建的表达载体是否能成功表达目的基因,将绿色荧光蛋白基因(gfp)在Nde I andXho I位点插入本发明所构建的表达载体中,生成一系列由不同启动子驱动gfp基因表达的载体。随后将这些质粒分别转入S.aureusUSA300_FPR3757中,利用氯霉素抗性筛选阳性目的菌落。
将得到的目的菌接种于TSB液体培养基中培养过夜。次日,取100μL接种于10mLTSB培养基中,培养6h至对数期期时,取200μL菌液,收集细菌并提取RNA,利用RT-qPCR检测每个菌株中gfp基因转录水平,如图5A结果所示,所有构建的表达载体都能在S.aureusUSA300_FPR3757中成功过表达gfp基因。
同时,取200μL菌液,抽提总蛋白,利用anti-his标签抗体,对重组表达的携带6*His标签的绿色荧光蛋白进行SDS-PAGE及Western blot检测。如图5B结果所示,所有载体也不同水平成功表达绿色荧光蛋白。说明本发明提供的金黄色葡萄球菌组成型启动子所构建的基因表达载体能够成功表达目的基因。
2.3、内源性基因(过氧化氢酶基因及转录抑制子purR)表达以验证本发明构建的基因过表达载体。
为了进一步评估本申请所构建的基因过表达载体,申请人随机挑选分别包含P00165(P10),P08620(P25),和P04400(P7)启动子的3个表达载体表达S.aureusUSA300_FPR3757的内源性基因:编码嘌呤生物合成通路的转录抑制子purR基因及过氧化氢酶基因(catalase)。以S.aureus USA300_FPR3757基因组DNA为模板,PCR扩增出purR及catalase基因,利用重组克隆法,在表达载体的Nde I、Xho I位点插入扩增的purR及catalase基因。测序验证后,将所得质粒转入S.aureusUSA300_FPR3757宿主菌中,得到相应过表达菌株。扩大培养过表达菌株,抽提RNA,利用荧光定量PCR,分别检测过purR及catalase基因表达水平。如图6A和6D所示,purR及catalase基因的表达水平在过表达菌株中明显高于野生型菌株。purR及catalase蛋白的过表达同时在蛋白水平得到验证,如图6B和6E所示,purR及catalase蛋白均在免疫印记(WB)中被检测到。
此外,过表达的purR的生物学活性得到验证,如图6C荧光定量PCR结果所示,purR转录抑制子所抑制的靶标基因(FnbA和FnbB),在过表达菌株中明显低于野生型菌株。另外,利用基于双氧水-钼酸铵的过氧化氢酶活性检测方法,过表达的catalase的生物学活性也得到验证,如图6F所示,过表达菌株细胞裂解液的过氧化氢酶活性明显高于野生型菌株。说明应用本申请的金黄色葡萄球菌组成型启动子构建的表达载体能够在金葡菌内成功表达两个内源蛋白过氧化氢酶(catalase)和嘌呤合成途径的转录抑制子(purR),并具备相应的生物学活性。因此本申请的金黄色葡萄球菌组成型启动子构建的表达载体能够为研究金葡菌耐药及毒力相关基因功能提供有效的支持。
以上所述,仅为本发明的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,可轻易想到变化或替换,都应涵盖在本发明的保护范围之内。因此,本发明的保护范围应以所述权利要求的保护范围为准。
序列表
<110> 四川大学华西医院
<120> 一种金黄色葡萄球菌组成型启动子、表达载体及其构建方法、重组菌株及应用
<130> 2022.01.04
<160> 20
<170> SIPOSequenceListing 1.0
<210> 1
<211> 235
<212> DNA
<213> 未知()
<400> 1
ttttacacca ctctcctcac tgtcattata cgatttagta caatctttta tcattatatt 60
gcctaactgt aggaaataaa tacttaactg ttaaatgtaa tttgtattta atattttaac 120
ataaaaaaaa ttacagttaa gaataaaaaa cgactagtta agaaaaattg gaaaataaat 180
gcttttagca tgttttaata taactagatc acagagatgt gatggaaaat agttg 235
<210> 2
<211> 434
<212> DNA
<213> 未知()
<400> 2
ggagattggg ttaaaaaggc gaagaatgaa ctggatgata ttagtaagaa attaaaaaat 60
attcaaagaa cggaagttta atagcttata tgattcttgg agctaagaca gcatgcgttc 120
attcatgcca ttattaatat aagcaccgca acaaaaaagc ttctaatgtg atacaggaac 180
ctcatattcc gtatcatgtt agaagctttt aatgtctaaa gaacatctac attttatcat 240
attttctgac ttattaaact tttatataat taaatatttc ttaattttcc aaaatagtga 300
taaatttgtg aaatacatca caaatccctt tatttatttg gaaattcatg taatattaga 360
cttgtaagaa gttaataaat agagagagac gagagagttt atataaatac tatataaaca 420
ttggagtgat gatt 434
<210> 3
<211> 247
<212> DNA
<213> 未知()
<400> 3
aataaccatt taatccttta tgtatttaat ttaattttag tatacacatt tatattacaa 60
aaatgaatgg ttaattaaaa atatatgggt atattcaata tatttattta aaaaaagcta 120
aaaatactta aaaaactata tacatatact aataatttat atattatttg agtaaggagc 180
actttttcaa aaaatagtgt ccctaaaaag ttttgataaa cttaaaatat tcaggaggtt 240
tctagtt 247
<210> 4
<211> 363
<212> DNA
<213> 未知()
<400> 4
acgtttaaca acacaagaat tattatatct aaatgaactt aaattagcaa taccttgtaa 60
ataaaaaatg tttatatttt tcactattat agagctattt atctaaaaag gttcaataag 120
acttaaatac gaattcaggc aacttaattg tgttaaatac agttttgaat gcctaactgt 180
atttcttttc tctttaaaat acagttaagt acattataag atgttgtgcg gataaacaaa 240
ctaattgtat caaatttatt ttaaaataac aacaacaaaa cgataagcga ataacatttc 300
ggtgatttaa aagctacgca cgtttttgtt atcttcaaat ttaaatttta aggagtgttt 360
tca 363
<210> 5
<211> 297
<212> DNA
<213> 未知()
<400> 5
ttaatataaa aaatatcaaa tcaaacacgt tgatatagat taaaatttta aaagtttaca 60
tatcagttaa gatacaaaat attcagacta ataattttca atttggcaaa atatcttaaa 120
catcaaatta ttataagaaa taaatgtatt taaccatatt ctagtaataa aaatattgaa 180
tttttatact tatttgttta gaatgaactt tataacatag ttggatagag tttcgattta 240
ataaattaca tgtgaacctt gctacaacaa gatgtgcatc agaggagtgg tttaata 297
<210> 6
<211> 350
<212> DNA
<213> 未知()
<400> 6
atattaatgg ctcagtaacg tgatgttgct gggcttttta atttaaacag gtatttatat 60
gatatttagg aatgagatgc tattacggat aaagtaaaat cctatatgca tgcgtgctac 120
tcatttattc ttatttttaa tttcacatgg ctagtgacta atacatcata aatcattagt 180
gattctttat tatttcagtc ccactccctc aagttaatga tgaatctatt tcgctagtta 240
taaaatgacg tcaaatcaat atcaaaaatt atttaagtaa aatgtttaga taatttttca 300
gtgggtaagt attatatata acatttaatt attccgagga ggcatttatt 350
<210> 7
<211> 235
<212> DNA
<213> 未知()
<400> 7
caactatttt ccatcacatc tctgtgatct agttatatta aaacatgcta aaagcattta 60
ttttccaatt tttcttaact agtcgttttt tattcttaac tgtaattttt tttatgttaa 120
aatattaaat acaaattaca tttaacagtt aagtatttat ttcctacagt taggcaatat 180
aatgataaaa gattgtacta aatcgtataa tgacagtgag gagagtggtg taaaa 235
<210> 8
<211> 150
<212> DNA
<213> 未知()
<400> 8
acatatcgtg agcaatgaac tgattatact taacattaaa aaagatgata acaccttcta 60
cacctccata tcacaaaaat tataacatta ttttgacata aatactacat ttgtaatata 120
ctacaaatgt agtcttatat aaggagtata 150
<210> 9
<211> 216
<212> DNA
<213> 未知()
<400> 9
tataacttgt tttgactagc tagcctaggt taaaatacaa ggtgagctta aatgtaagct 60
atcatcttta tagtttgatt ttttggggtg aatgcattat aaaagaattg taaaattctt 120
tttgcatcgc tataaataat ttctcatgat ggtgagaaac tatcatgaga gataaattta 180
aatattattt ttaattagaa taggagagat tttata 216
<210> 10
<211> 120
<212> DNA
<213> 未知()
<400> 10
gggtgtaaat tatatgctaa aaatatcaga aaattcaaag tgtttgcgtt tgcacgatag 60
cgtaaaaatg ttaaaatata ataaagagtt accaataaag aggtttaagg agagattact 120
<210> 11
<211> 301
<212> DNA
<213> 未知()
<400> 11
ctagccatca ttttcaattt attagacaat ttcaaacttt ttttattttc attcaattaa 60
cctttaattg aaagctattc tcaactttcc ttttaaatat gaagcaattt tttcaaaaac 120
gctattagtc acaaaatgta cacataattt taacaaatgt gtgaacccac gtcacacctt 180
gatttatcaa catttttgat acaattttat taattttttt cccataagcc cttgtaaata 240
ttgtgtaata acttaaaatt aatgttaagc cctacatttg tagtattagg aggtcaaaaa 300
a 301
<210> 12
<211> 217
<212> DNA
<213> 未知()
<400> 12
ctttatcctc caatctactt ataaaatatt gtaattaatg actacatatt atgcaacggc 60
ttaaattgta taaaaatgta tacgtttgca tttagtataa ctatcgcatt tttcaaaaaa 120
tacacattta atctgcagta tttcaatgca ttgacgctat ttttttgata taattacttt 180
gaaaaatacg tgcgtaagca ctcaaggagg aactttc 217
<210> 13
<211> 356
<212> DNA
<213> 未知()
<400> 13
attcattcac caccgttctt atgactaatt atatagaata attttcaatg ataataataa 60
aatgattcaa ggtacgaatt tacaataaag aaggaaataa aaaatatctc gaaaatagtt 120
gaactgacta agtatataaa gtaaaatata aaagtatgtg ttagacagat agaaaaatta 180
tgtgaaaagc cttgatttat cgatgttttt cgtgtaatat aactaacgtt ggactttaag 240
aaaagcgatg aagcgaaagg ttactgacac acccggccgc tttgccatgg cgctgtgtaa 300
gatagttttc gtggagaagt ctatcactaa atgtagacga ataaggaggg aaaatt 356
<210> 14
<211> 239
<212> DNA
<213> 未知()
<400> 14
ttgccattga caaaaagctt gtgaaattat aagattatta acggtattgt tttatatcca 60
ccccacgata agccccggaa acttattgtg ttacaagata tataagcaga aacgaacaac 120
agttaacaaa ataaatgaaa ttaaacgttt taaaaatgaa acaaatgaaa tcatctatta 180
ggttatgaaa ctgtttatag cttgaataga agcatttatt ttttaggagg acaattatt 239
<210> 15
<211> 174
<212> DNA
<213> 未知()
<400> 15
ttaataatga ggttttattt acaaaaacta gggaatatat tactaaatgg tacttcatct 60
tatatattaa aaataaattt aaagttatta atttattatg tttaagaaaa aaactgatgg 120
gtacatattt aatatgtttt taaattaact ttaactaagg aggtgtcgtt aggg 174
<210> 16
<211> 216
<212> DNA
<213> 未知()
<400> 16
tttttgtacg tcaaaactta tacaaaaatt ttaaaaataa tgtaagcacg aaacttttaa 60
ttagtacaca attgataaca tttttcaacg ttcatcattt tgtcaaaaac tcaaaagtaa 120
attagaaaga ttataattta tttaagcatc gtacttaatt ggattttaaa ttatgttata 180
atatttgtat tgttagtata tatgggggcg tttcaa 216
<210> 17
<211> 180
<212> DNA
<213> 未知()
<400> 17
ttaacaatta aagttattaa actaaccaaa agataaaaaa gagtattgat tttttaatta 60
gaaaagtgtt aaaattatgt ggtcgcgctt ttagagcgcc catttcgtca cgaaatgtta 120
agagtgggag ggcaaaactg agccctgtga ccacatcacg atatcaagga ggtgcacatc 180
<210> 18
<211> 271
<212> DNA
<213> 未知()
<400> 18
taaatgatat aaacaattac aggctgaaag aaatatcttt cagtctgtaa aaatatattg 60
acaataagta atttccaagt tatattactt attgtgatta ttttacctaa gacagtagga 120
gttatttata acttaaaatt tatcctgccg aggctaaaat tgacttgaac gtgatgatct 180
atgatctttc aagcactttt tgccgtgggt agaaagtgct ttttttatta attttaaaaa 240
aagcaccaaa aatttaaatg gaggtgtctg a 271
<210> 19
<211> 150
<212> DNA
<213> 未知()
<400> 19
gaatatgtag atacaagtga agatttagac ggatacatgt tttatattta atcgtataaa 60
tactatacta taacataaaa acttcatatt ataatgttta gcgaacctcc ttagtggtat 120
ataaatatat acatccaagg aggtttcact 150
<210> 20
<211> 264
<212> DNA
<213> 未知()
<400> 20
ctgatatttt tgactaaacc aaatgctaac ccagaaatac aatcactgtg tctaatgaat 60
aatttgtttt ataaacactt ttttgtttac ttctcatttt taattagtta taattaacta 120
aataatagag cattaaatat atttaataaa acttatttaa tgcaaaatta tgactaacat 180
atctataata aataaagatt agatatcaat atattatcgg gcaaatgtat cgagcaagat 240
gcatcaaata gggaggtttt aaac 264
Claims (7)
1.一种金黄色葡萄球菌组成型启动子,其特征在于,所述组成型启动子的核苷酸序列如SEQ ID NO.1所示。
2.一种包含权利要求1所述的金黄色葡萄球菌组成型启动子的表达载体。
3.根据权利要求2所述的表达载体,其特征在于,所述表达载体是在大肠杆菌-金黄色葡萄球菌穿梭质粒插入权利要求1所述的组成型启动子构建而成。
4.一种如权利要求2所述的表达载体的构建方法,其特征在于,包括:
在大肠杆菌-金黄色葡萄球菌穿梭载体质粒pBUS1-Pcap-HC的BglII位点插入氯霉素抗性基因,得到携带氯霉素抗性基因的pBUS1_Pcap_HC_cat质粒;
利用限制性内切酶KpnI和NdeI切掉pBUS1_Pcap_HC_cat质粒中的Pcap启动子,并替换为权利要求1所述的组成型启动子,得到携带组成型启动子的基因表达载体。
5.一种包括权利要求2所述的表达载体的重组菌株。
6.根据权利要求5所述的重组菌株,其特征在于,所述重组菌株是在表达载体的NdeI和XhoI位点插入绿色荧光蛋白基因GFP,以形成由权利要求1所述的组成型启动子驱动GFP基因表达的载体质粒;并将所形成的载体质粒转入MRSA的S.aureusUSA300_FPR3757菌株中培养形成。
7.权利要求1所述的金黄色葡萄球菌组成型启动子在制备抗金黄色葡萄球菌感染的药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210006664.3A CN114480387B (zh) | 2022-01-05 | 2022-01-05 | 一种金黄色葡萄球菌组成型启动子、表达载体及其构建方法、重组菌株及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210006664.3A CN114480387B (zh) | 2022-01-05 | 2022-01-05 | 一种金黄色葡萄球菌组成型启动子、表达载体及其构建方法、重组菌株及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114480387A CN114480387A (zh) | 2022-05-13 |
CN114480387B true CN114480387B (zh) | 2023-08-25 |
Family
ID=81509415
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210006664.3A Active CN114480387B (zh) | 2022-01-05 | 2022-01-05 | 一种金黄色葡萄球菌组成型启动子、表达载体及其构建方法、重组菌株及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114480387B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101503677A (zh) * | 2008-12-26 | 2009-08-12 | 四川大学华西医院 | Survivin启动子调控人NIS基因的重组腺病毒及其构建方法和应用 |
CN103320461A (zh) * | 2013-06-19 | 2013-09-25 | 中国农业科学院饲料研究所 | 在Pichia pastoris中组成型表达靶向抗菌肽AgPlectasin的方法 |
CN103333849A (zh) * | 2013-07-08 | 2013-10-02 | 中国人民解放军第三军医大学 | 金黄色葡萄球菌突变株及其制备方法和应用 |
CN104531737A (zh) * | 2014-12-17 | 2015-04-22 | 中国科学技术大学 | 一种新型的金黄色葡萄球菌荧光标记系统 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7521221B2 (en) * | 2005-11-21 | 2009-04-21 | Board Of Trustees Of The University Of Arknasas | Staphylococcus aureus strain CYL1892 |
FR2899110A1 (fr) * | 2006-03-31 | 2007-10-05 | Sanofi Pasteur Sa | Polysaccharides capsulaires de type 5 et de type 8 des souches surproductrices de staphylococcus aureus |
FR2945049B1 (fr) * | 2009-04-30 | 2013-10-04 | Pherecydes Pharma | Modification du genome d'un bacteriophage lytique par immobilisation dudit bacteriophage dans sa bacterie hote |
US20190233906A1 (en) * | 2015-08-26 | 2019-08-01 | Universidad Pública de Navarra | Mutant strains of staphylococcus aureus with multiple inactivated tcs systems |
-
2022
- 2022-01-05 CN CN202210006664.3A patent/CN114480387B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101503677A (zh) * | 2008-12-26 | 2009-08-12 | 四川大学华西医院 | Survivin启动子调控人NIS基因的重组腺病毒及其构建方法和应用 |
CN103320461A (zh) * | 2013-06-19 | 2013-09-25 | 中国农业科学院饲料研究所 | 在Pichia pastoris中组成型表达靶向抗菌肽AgPlectasin的方法 |
CN103333849A (zh) * | 2013-07-08 | 2013-10-02 | 中国人民解放军第三军医大学 | 金黄色葡萄球菌突变株及其制备方法和应用 |
CN104531737A (zh) * | 2014-12-17 | 2015-04-22 | 中国科学技术大学 | 一种新型的金黄色葡萄球菌荧光标记系统 |
Non-Patent Citations (1)
Title |
---|
Identification and Application of a Panel of Constitutive Promoters for Gene Overexpression in Staphylococcus aureus;Qiang Liu等;Front Microbiol;1-14 * |
Also Published As
Publication number | Publication date |
---|---|
CN114480387A (zh) | 2022-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230287439A1 (en) | Pathway integration and expression in host cells | |
CN102703424B (zh) | 一种重组工程介导的大肠杆菌基因组点突变的方法 | |
US10738314B2 (en) | IrrE protein functional domain for improving anti-oxidation capability of cell and application thereof | |
CN110760511B (zh) | 一种用于治疗杜氏肌营养不良症的gRNA、表达载体、CRISPR-Cas9系统 | |
CN111235164B (zh) | 一种疫霉菌抗性的负调控因子AtPPR1基因及其同源基因的应用 | |
CN110382697A (zh) | 用于治疗α-1抗胰蛋白酶缺乏症的组合物及方法 | |
Ianiri et al. | Approaches for genetic discoveries in the skin commensal and pathogenic Malassezia yeasts | |
JP5729702B2 (ja) | コウジ酸の産生に必須の遺伝子を利用してコウジ酸の産生量を向上する方法 | |
KR20190005707A (ko) | 디옥시바이오라세인 생산능이 향상된 재조합 미생물 및 그를 이용한 디옥시바이오라세인을 생산하는 방법 | |
Su et al. | Insights into the roles of two genes of the histidine biosynthesis operon in pathogenicity of Xanthomonas oryzae pv. oryzicola | |
Du et al. | Characterization of a pathway− specific activator of edeine biosynthesis and improved edeine production by its overexpression in Brevibacillus brevis | |
KR102304761B1 (ko) | StSR4 유전자 교정에 의해 병 저항성이 증가된 감자 식물체의 제조방법 및 상기 방법에 의해 제조된 병 저항성이 증가된 유전체 교정 감자 식물체 | |
WO2021224152A1 (en) | Improving expression in fermentation processes | |
CN114480387B (zh) | 一种金黄色葡萄球菌组成型启动子、表达载体及其构建方法、重组菌株及应用 | |
CN113234723A (zh) | 一种日本鳗鲡细胞因子il-6基因启动子及其应用 | |
CN113943690B (zh) | 魏氏柠檬酸杆菌tpiA基因敲除突变株及其应用 | |
CN116478260A (zh) | 一种小麦糖转运蛋白、基因及其应用 | |
CN114891806B (zh) | 一种魏氏柠檬酸杆菌yqjH基因敲除突变株及其应用 | |
CN115838713A (zh) | 一种蛋白酶及其在l-肌肽合成中的应用 | |
CN104046647A (zh) | 一种重组工程介导的苜蓿中华根瘤菌Rm1021基因敲除方法 | |
Barrault et al. | Staphylococcal sRNA IsrR down-regulates methylthiotransferase MiaB under iron-deficient conditions | |
Chen et al. | Multiple-copy-gene integration on chromosome of Escherichia coli for beta-galactosidase production | |
CN109293751B (zh) | 鼠疫耶尔森菌毒力相关蛋白sORF34及其编码基因与应用 | |
EA009058B1 (ru) | Уменьшение частоты спонтанных мутаций в клетках | |
Luo et al. | Strand-specific RNA-Seq analysis provides first insight into transcriptome response of Vibrio alginolyticus to phage infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |